Bronchodilator effects of ipratropium bromide and albuterol sulfate among subjects with tetraplegia.
In addition to lung volume restriction, persons with chronic tetraplegia demonstrate obstructive airway physiology evinced by pharmacologically-induced bronchodilation. We previously found independent evidence that anticholinergic agents (ipratropium bromide; IB) and beta-2 adrenergic agonists (albuterol sulfate; AS) were associated with significant bronchodilation in subjects with tetraplegia as determined via spirometry or body plethysmography. Direct comparison of these two classes of agents has received little attention.



Twelve subjects with chronic tetraplegia completed single dose treatment on alternate days with nebulized IB or AS. Patients underwent pre- and 30-minute post-bronchodilator spirometry, body plethysmography, and impulse oscillation system (IOS) in accordance with established protocols.



Spirometry and specific airway conductance revealed significant bronchodilator responsiveness following both IB and AS. As determined by increases in specific airway conductance post-bronchodilator, IB tended toward greater bronchodilation than AS (71% vs. 47%). IOS revealed a greater reduction in central airway resistance (R20) following IB compared to AS (22% vs. 9%, P < 0.01). A greater number of subjects exhibited a clinically significant reduction in R20 following IB compared to AS (58% vs. 8%, P < 0.01).



Among subjects with tetraplegia, both IB and AS elicit significant bronchodilation, although the magnitude of the bronchodilator response is greater following IB. This lends support to theory of overriding cholinergic airway tone in tetraplegia. The IOS findings further suggest that the predominant site of action of IB is upon the larger central airways congruent with findings in able-bodied subjects.
a VA RR&D National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center , Bronx , NY , USA.|b Medical Service, James J. Peters VA Medical Center , Bronx NY , USA.|c Departments of Medicine and Rehabilitation Medicine , Icahn School of Medicine at Mount Sinai , New York , NY , USA.
Gregory J
GJ
Schilero
a VA RR&D National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center , Bronx , NY , USA.
Joshua C
JC
Hobson
a VA RR&D National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center , Bronx , NY , USA.|b Medical Service, James J. Peters VA Medical Center , Bronx NY , USA.
Kamaldeep
K
Singh
a VA RR&D National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center , Bronx , NY , USA.|c Departments of Medicine and Rehabilitation Medicine , Icahn School of Medicine at Mount Sinai , New York , NY , USA.
Ann M
AM
Spungen
a VA RR&D National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center , Bronx , NY , USA.|b Medical Service, James J. Peters VA Medical Center , Bronx NY , USA.|c Departments of Medicine and Rehabilitation Medicine , Icahn School of Medicine at Mount Sinai , New York , NY , USA.
William A
WA
Bauman
a VA RR&D National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center , Bronx , NY , USA.|b Medical Service, James J. Peters VA Medical Center , Bronx NY , USA.|c Departments of Medicine and Rehabilitation Medicine , Icahn School of Medicine at Mount Sinai , New York , NY , USA.
Miroslav
M
Radulovic
D000328:Adult; D000420:Albuterol / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011782:Quadriplegia / Q000150:complications*; D012131:Respiratory Insufficiency / Q000188:drug therapy* / Q000209:etiology
D001993:Bronchodilator Agents; D009241:Ipratropium; D000420:Albuterol
Bronchodilator; Pulmonary function; Spinal cord injury; Tetraplegia